Juvenile Arthritis News

Despite often being grouped together in practice, adults with polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis are distinct, with markedly different medication needs, according to findings published in the Journal of Clinical Rheumatology.

Children born to mothers treated with TNF inhibitors for rheumatoid arthritis did not demonstrate an increased risk for infection, compared with both unexposed offspring and the general population, according to findings published in Arthritis & Rheumatology.

Making long-term outcome predictions of remission off medication, functional disability and joint damage may be feasible in juvenile idiopathic arthritis based on early clinical assessment, according to findings published in Arthritis Research and Therapy.

Fat pad tissue and physiological vascularity have been added to the identified and tested definitions of joint components that can be visualized in ultrasonography in healthy children at various age groups, according to research published in Pediatric Rheumatology.

DESTIN, Fla. — Although the incidence of rheumatologic adverse effects associated with immune checkpoint inhibitors is expected to grow with their increased use, these effects remain poorly studied in random clinical trials, according to findings presented at the 2018 Congress of Clinical Rheumatology.

DESTIN, Fla. — In-hospital deaths among patients with adult-onset Still’s disease was significantly higher among those with disseminated intravascular coagulation and Asian ethnicity, according to findings presented at the 2018 North American Young Rheumatology Investigator Forum.

The FDA has approved the subcutaneous formulation of Actemra for the treatment of polyarticular juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release from Genentech.

Among patients with systemic juvenile idiopathic arthritis, tocilizumab led to a 35% response rate during the first 12 weeks of treatment, and yielded a combined remission and inactive-disease rate of 75% after 1 year, according to findings published in Pediatric Rheumatology.

BOSTON — The potential rheumatic side effects of checkpoint inhibitor therapy in patients with cancer can include arthralgia, arthritis, polymyalgia rheumatica, giant cell arteritis, myositis, sicca syndrome and systemic lupus erythematosus, and can be chronic in approximately 50% of patients, according to findings presented here.

Although children diagnosed with juvenile spondyloarthritis demonstrate a low rate of symptomatic activity at onset, there is a marked increase in axial involvement in most patients after 5 years, according to findings published in Pediatric Rheumatology.